Canaccord raises Taysha Gene Therapies price target on trial progress.
Share this article
Corporate
Score 35
Bullish
Canaccord raises Taysha Gene Therapies price target on trial progress
Apr 06, 2026 11:57 UTC
TAYSA
Short term
Related Articles
Score 15
Form 13F Israel Discount Bank of New York For: 6 April
Apr 06, 15:15
Score 45
Italy Considers Leadership Shift at Leonardo Amid Strategic Appointments
Apr 06, 15:14
Score 15
Daniel Meuser of Pennsylvania’s 9th district partially sells NVIDIA stock
Apr 06, 15:07
Score 25
Kevin Hern makes significant sales in Accenture, Texas Instruments, and SmartStop Self Storage stocks
Apr 06, 15:06
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.